Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma (NCT02229071) | Clinical Trial Compass
CompletedPhase 1/2
Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma
China106 participantsStarted 2014-04
Plain-language summary
This phase IB study of donafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, is to assess toxicity,efficacy and pharmacokinetics in patients wiht advanced hepatocellular carcinoma (HCC) .
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 18 -70 years old
* Patients with measurable, histologically proven, inoperable HCC
* Child-Pugh (CP) score of A
* Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less.
* Patients received prior systemic treatments for HCC before 4 weeks
* Patients received operate before 3 months
* Patients received TACE before 4 weeks
* Life expectancy at least 3 months
* Adequate hepatic and renal function
* Adequate hematologic function (platelet count,≥70×109per liter;hemoglobin ≥8.5 g per deciliter)
* Prothrombin time international normalized ratio≤2; or prothrombin time ≤16 seconds;or APTT≤43s;or TT≤21s.
Exclusion Criteria:
* Patients had prior treatment with sorafenib
* CNS involvement.